[Parathyroid and bone. Role of parathyroid hormone in the treatment of osteoporosis].
Parathyroid hormone (PTH) , a potent anabolic agent, produces larger increments in bone mass than those seen with antiresorptive agents. No further benefit is expected in PTH and antiresorptive combinations in treatment-naïve patients of osteoporosis, but in cases achieving the plateau level of BMD with established alendronate PTH can stimulate bone formation and increase BMD again. Alendronate treatment after PTH therapy can maintain gains in BMD at lumbar spine and hip as well. Many possibilities are expected in the role of PTH therapy in osteoporosis treatment.
Nakamura
Toshitaka
T
University of Occupational and Environmental Health, Department of Orthopedics School of Medicine.
D000368:Aged; D000369:Aged, 80 and over; D019386:Alendronate / Q000008:administration & dosage / Q000494:pharmacology; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008875:Middle Aged; D010012:Osteogenesis / Q000187:drug effects; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000378:metabolism; D010281:Parathyroid Hormone / Q000008:administration & dosage* / Q000494:pharmacology / Q000502:physiology; D013268:Stimulation, Chemical
D050071:Bone Density Conservation Agents; D010281:Parathyroid Hormone; D019386:Alendronate